Aligos Therapeutics (ALGS) Gains from Investment Securities (2021 - 2025)
Historic Gains from Investment Securities for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $4.2 million.
- Aligos Therapeutics' Gains from Investment Securities changed N/A to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 7953.13%. This contributed to the annual value of $46.1 million for FY2024, which is 202687.87% up from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' Gains from Investment Securities is $4.2 million.
- Aligos Therapeutics' 5-year Gains from Investment Securities high stood at $62.1 million for Q4 2024, and its period low was -$61.5 million during Q1 2025.
- Over the past 5 years, Aligos Therapeutics' median Gains from Investment Securities value was $184000.0 (recorded in 2021), while the average stood at $1.9 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 5978750.0% in 2024, then crashed by 52784.39% in 2025.
- Aligos Therapeutics' Gains from Investment Securities (Quarter) stood at $2.2 million in 2021, then crashed by 101.23% to -$27000.0 in 2022, then skyrocketed by 4081.48% to $1.1 million in 2023, then skyrocketed by 5679.81% to $62.1 million in 2024, then crashed by 93.23% to $4.2 million in 2025.
- Its last three reported values are $4.2 million in Q3 2025, -$1.7 million for Q2 2025, and -$61.5 million during Q1 2025.